What The Global Pharmaceutical Industry Is Planning In 2010-2011: Procurement, Investment & Industry Trends Outlook

“What The Global Pharmaceutical Industry Is Planning In 2010-2011” is a new report published by ICD Research that analyzes how drug manufacturing companies products & services spend, procurement strategies & practices and business planning will be shaped in 2010 to 2011. In an uncertain economic climate this report gives you access to the category-level spending outlooks, buyer budgets, supplier selection criteria, business challenges and investment opportunities of leading purchase decision makers. The report also identifies buyers and suppliers market growth, M&A and investment expectations. The research is based on an extensive survey of senior and C-level industry executives from our market leading panels.

SCOPE

• Opinions and forward looking statements of over 320 industry executives are captured in our in-depth survey, of which 49% represent Directors, C-levels & Departmental Heads
• Analysis on buyer spend, procurement and industry developments by pharmaceutical process and manufacturing, biopharma, biotech, public sector pharma, CRO and CMO companies and leading suppliers worldwide
• Key topics include buyer spend activity, procurement behaviors & strategies, threats & opportunities for the drug manufacturing industry and how these have been affected by the economic uncertainty
• In the report buyers identify what suppliers need to do to maintain their business and the key actions being taken by industry players to overcome the leading business threats
• The research is based on primary survey research conducted by ICD Research accessing its B2B panels comprised of senior purchase decision makers and leading supplier organizations
• The geographical scope of the research is global – drawing on the activity and expectations of leading industry players across the Americas, Europe, Asia-Pacific and Africa & Middle East

REASONS TO BUY

• Drive revenues by understanding future product investment areas and growth regions by leading industry players
• Formulate effective sales & marketing strategies by identifying how buyer budgets are changing and where spend will be directed to in the future
• Better promote your business by aligning your capabilities and business practices with your customers’ changing needs during these times of market uncertainty
• Secure stronger customer relationships by understanding the leading business concerns and changing strategies of buyers in the pharmaceutical industry
• Predict how the industry will grow, consolidate and where it will stagnate
• Uncover the business outlook, key challenges and opportunities identified by suppliers and buyers in the industry

KEY HIGHLIGHTS

• The majority of pharmaceutical industry respondents identified the US, Canada and Singapore, Taiwan and Hong Kong to be the fastest growing markets in next 12 months among developed nations due to new approaches to customer needs, product affordability, effective distribution and rise of these regions as clinical trial destinations
• The majority of pharmaceutical companies will be increasing procurement spend over the next 12 months. The average size of the global, annual procurement budgets among pharmaceutical companies is US$122m.
• 35% of pharmaceutical industry buyers agree that in order to maintain and win their business, suppliers will have to innovate product

Contents

CHAPTER 1: EXECUTIVE SUMMARY

CHAPTER 2: INTRODUCTION

Heading: Profile Of Survey Respondents

CHAPTER 3: INDUSTRY DYNAMICS

Heading: Revenue Growth Expectations In The Pharmaceutical Industry
Heading: Future Developments In Competitive Structure In The Industry
Heading: Merger And Acquisition Activity Predictions

CHAPTER 4: PHARMACEUTICAL MARKET GROWTH OUTLOOK

Heading: Regional Growth Forecasts In The Pharmaceutical Industry By Country
Heading: Market Growth Forecasts By Industry Sector

CHAPTER 5: THREATS AND OPPORTUNITIES FOR THE PHARMACEUTICAL INDUSTRY

Heading: Leading Business Concerns For The Period 2010-2011
Heading: Key Actions To Overcome Business Threats: Cost Management
Heading: Key Actions To Overcome Business Threats: Driving Sales
Heading: Key Supplier Actions To Maintain And Win Buyer Business

CHAPTER 6: PHARMACEUTICAL INDUSTRY BUYER SPEND ACTIVITY

Heading: Annual Procurement Budgets: Pharmaceutical Industry
Heading: Procurement Cost Saving Targets In The Pharmaceutical Industry
Heading: Planned Change In Procurement Spend
Heading: Planned Change In Procurement Spend By Product And Service Category

CHAPTER 7: PROCUREMENT BEHAVIORS AND STRATEGIES

Heading: Critical Success Factors For Supplier Selection
Heading: Expected Future Changes In Procurement Objectives
Heading: Areas Of Future Value Creation In Procurement Strategy
Heading: Mitigating Supplier Failure And Maintaining Business Continuity
Heading: Planning Against Business Supply Contingencies

CHAPTER 8: APPENDIX

LIST OF TABLES

Table 1: Count Of Global Pharmaceutical Industry Survey Respondents By Company Type (Number Of Respondents), 2010 Industry Survey
Table 2: Buyer Respondents By Job Role (% Buyer Respondents), Global Pharmaceutical Industry, 2010
Table 3: Buyer Respondents By Organization's Global Turnover (% Buyer Respondents), Global Pharmaceutical Industry, 2010
Table 4: Buyer Respondents By Organization's Total Employee Size (% Buyer Respondents), Global Pharmaceutical Industry, 2010
Table 5: Buyer Respondents By Region (% Buyer Respondents), Global Pharmaceutical Industry, 2010
Table 6: Supplier Respondents By Job Role (% Supplier Respondents), Global Pharmaceutical Industry, 2010
Table 7: Supplier Respondents By Organization's Global Turnover (% Supplier Respondents), Global Pharmaceutical Industry, 2010
Table 8: Supplier Respondents By Organization's Total Employee Size (% Supplier Respondents), Global Pharmaceutical Industry, 2010
Table 9: Supplier Respondents By Region (% Supplier Respondents), Global Pharmaceutical Industry, 2010
Table 10: Company Revenue Growth Optimism Trend By Global Pharmaceutical Industry Company Type: Pharmaceutical Manufacturers, CRO / CMO Companies, Pharmaceutical Industry Suppliers, Pharmaceutical Industry Suppliers (% All Respondents), 2009-2010
Table 11: Company Revenue Growth Optimism Trend In The Global Pharmaceutical Industry By Region: North America, Europe, Asia-Pacific, Rest Of The World (% All Respondents), 2009-2010
Table 12: Company Revenue Growth Optimism In The Global Pharmaceutical Industry By Turnover (% All Respondents), 2010
Table 13: Pharmaceutical Manufacturer Industry: Market Predictions Of The Fastest And Slowest Growing Regions (% Pharmaceutical Manufacturer Respondents), 2010
Table 14: CRO / CMO Company Industry: Market Predictions Of The Fastest And Slowest Growing Regions (% CRO / CMO Company Respondents), 2010
Table 15: Pharmaceutical Industry Supplier Industry: Market Predictions Of The Fastest And Slowest Growing Regions (% Pharmaceutical Industry Supplier Respondents), 2010
Table 16: Pharmaceutical Manufacturer Predictions Of The Fastest And Slowest Growing Industry Sectors (% Pharmaceutical Manufacturer Respondents), 2010
Table 17: CRO / CMO Company Predictions Of The Fastest And Slowest Growing Industry Sectors (% CRO / CMO Company Respondents), 2010
Table 18: Pharmaceutical Industry Supplier Predictions Of The Fastest And Slowest Growing Industry Sectors (% Pharmaceutical Industry Supplier Respondents), 2010
Table 19: Global Pharmaceutical Industry Predictions Of The Fastest And Slowest Growing Industry Sectors By Region: North America, Europe, Asia-Pacific, Rest Of The World (% 'Very Strong Growth' And 'Strong Growth' Combined, All Respondents), 2010
Table 20: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. Vs. Pharmaceutical Industry Supplier Vs.: Leading Business Concerns For The Period 2010-2011 Among Global Pharmaceutical Industry Buyers And Suppliers (% All Respondents), 2010
Table 21: Leading Business Concerns For The Period 2010-2011 Among Global Pharmaceutical Industry Buyers And Suppliers By Region: North America, Europe, Asia-Pacific, Rest Of The World (% All Respondents), 2010
Table 22: Leading Business Concerns For The Period 2010-2011 Among Global Pharmaceutical Industry Buyers And Suppliers By Company Turnover (% All Respondents), 2010
Table 23: Most Important Actions Being Implemented To Facilitate Cost Containment In 2010-2011 In The Global Pharmaceutical Industry (% All Respondents), 2010
Table 24: Most Important Actions Being Implemented To Facilitate Cost Containment In 2010-2011 In The Global Pharmaceutical Industry – Senior Level Responses Only (% Ceo/Md/Board Level Respondents), 2010
Table 25: Most Important Actions Being Implemented To Facilitate Cost Containment In 2010-2011 In The Global Pharmaceutical Industry: Buyer Vs. Supplier Comparison (% All Respondents), 2010
Table 26: Most Important Actions Being Implemented For Driving Sales To Overcome Present Business Challenges In 2010-2011 In The Global Pharmaceutical Industry (% All Respondents), 2010
Table 27: Most Important Actions Being Implemented For Driving Sales To Overcome Present Business Challenges In 2010-2011 In The Global Pharmaceutical Industry – Senior Level Responses Only (% Ceo/Md/Board Level Respondents), 2010
Table 28: Most Important Actions Being Implemented For Driving Sales To Overcome Present Business Challenges In 2010-2011 In The Global Pharmaceutical Industry: Buyer Vs. Supplier Comparison (% All Respondents), 2010
Table 29: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Supplier Responses Vs. All Buyer Responses (% All Respondents), 2010
Table 30: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. (% Buyer Respondents), 2010
Table 31: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Analysis Of Buyer Respondents By Company Turnover (% Buyer Respondents), 2010
Table 32: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Analysis Of All Buyer Respondents By Procurement Budget (% Buyer Respondents), 2010
Table 33: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Analysis Of All Buyer Respondents By Region (% Buyer Respondents), 2010
Table 34: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Analysis Of All Buyer Respondents By Purchasing Decision Seniority (% Buyer Respondents With Purchasing Decision Influence), 2010
Table 35: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. (% All Buyer Respondents), 2010
Table 36: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry By Company Turnover (% All Buyer Respondents), 2010
Table 37: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry By Region (% All Buyer Respondents), 2010
Table 38: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry By Region (% All Buyer Respondents), 2009
Table 39: Projected Procurement Cost Savings Targets In The Global Pharmaceutical Industry For 2010-2011: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. (% All Buyer Respondents), 2010
Table 40: Projected Procurement Cost Savings Targets In The Global Pharmaceutical Industry For 2010-2011 By Company Turnover: (% All Buyer Respondents), 2010
Table 41: Projected Procurement Cost Savings Targets In The Global Pharmaceutical Industry For 2010-2011 By Region: (% All Buyer Respondents), 2010
Table 42: Projected Procurement Cost Savings Targets In The Global Pharmaceutical Industry For 2010-2011 By Leading Business Concern (Cost Containment): (% All Buyer Respondents), 2010
Table 43: Expected Change In Total Procurement Spend In The Global Pharmaceutical Industry Over The Next 12 Months: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents) 2010 (With Comparison To 2009 Expectations)
Table 44: Expected Change In Total Procurement Spend In The Global Pharmaceutical Industry Over The Next 12 Months By Company Turnover (% All Buyer Respondents), 2010 (With Comparison To 2009 Expectations)
Table 45: Expected Change In Total Procurement Spend In The Global Pharmaceutical Industry Over The Next 12 Months By Region (% All Buyer Respondents), 2010
Table 46: Proportion Of Industry Players Planning to Increase or Decrease Planned Spend Level in 2010: Global Pharmaceutical Industry Comparison Vs. Other Industries (% All Respondents), 2010
Table 47: Future Change In Spend In The Global Pharmaceutical Industry By Product And Service Category: Pharmaceutical Manufacturer - Expected Increase Or Decrease Over The Next 12 Months (% Pharmaceutical Manufacturer Respondents), 2010
Table 48: Future Change In Spend In The Global Pharmaceutical Industry By Product And Service Category: CRO / CMO Company - Expected Increase Or Decrease Over The Next 12 Months (% CRO / CMO Company Respondents), 2010
Table 49: Critical Success Factors For Selecting A Pharmaceutical Industry Supplier: Buyer Vs. Supplier Comparison (% All Respondents), Global, 2010
Table 50: Critical Success Factors For Selecting A Pharmaceutical Industry Supplier: Pharmaceutical Manufacturer Vs. CRO / CMO Company Comparison (% All Buyer Respondents), Global, 2010
Table 51: Pharmaceutical Manufacturer Attitudes And Approaches To Existing Procurement Practices: Level Of Agreement To The Following Statement (% Pharmaceutical Manufacturer Respondents), 2010
Table 52: CRO / CMO Company Attitudes And Approaches To Existing Procurement Practices: Level Of Agreement To The Following Statement (% CRO / CMO Company Respondents), 2010
Table 53: Expected Changes In Procurement Strategy In The Global Pharmaceutical Industry To Drive Value Across The Business: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010
Table 54: Expected Changes In Procurement Strategy In The Global Pharmaceutical Industry To Drive Value Across The Business: All Buyers By Company Turnover (% All Buyer Respondents), 2010
Table 55: Expected Changes In Procurement Strategy In The Global Pharmaceutical Industry To Drive Value Across The Business: All Buyers By Purchasing Decision Seniority (% All Buyer Respondents Purchasing Decision Influence), 2010
Table 56: Expected Changes In Procurement Strategy In The Global Pharmaceutical Industry To Drive Value Across The Business: All Buyers By Region (% All Buyer Respondents), 2010
Table 57: Pharmaceutical Manufacturer Attitudes And Approaches To Existing Procurement Practices: Level Of Agreement To The Following 3 Statements (% Pharmaceutical Manufacturer Respondents), 2010
Table 58: CRO / CMO Company Attitudes And Approaches To Existing Procurement Practices: Level Of Agreement To The Following 3 Statements (% CRO / CMO Company Respondents), 2010
Table 59: Critical Strategies Adopted By Buyers To Ensure Business Continuity In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010
Table 60: Critical Strategies Adopted By Buyers To Ensure Business Continuity In The Global Pharmaceutical Industry By Company Turnover: (% All Buyer Respondents), 2010
Table 61: Pharmaceutical Manufacturer Attitudes And Approaches To Existing Procurement Practices: Level Of Agreement To The Following Statement (% Pharmaceutical Manufacturer Respondents), 2010
Table 62: CRO / CMO Company Attitudes And Approaches To Existing Procurement Practices: Level Of Agreement To The Following Statement (% CRO / CMO Company Respondents), 2010
Table 63: Actions Undertaken By Buyers To Survive Product/Service Inflation And/Or Supply Shortages In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010
Table 64: Actions Undertaken By Buyers To Survive Product/Service Inflation And/Or Supply Shortages In The Global Pharmaceutical Industry By Company Turnover: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010
Table 65: Full Survey Results - Closed Questions

LIST OF FIGURES

Figure 1: Company Revenue Growth Optimism Trend In The Global Pharmaceutical Industry (% All Respondents), 2009-2010
Figure 2: Company Revenue Growth Optimism Trend By Global Pharmaceutical Industry Company Type: Pharmaceutical Manufacturers, CRO / CMO Companies, Pharmaceutical Industry Suppliers, Pharmaceutical Industry Suppliers (% All Respondents), 2009-2010
Figure 3: Company Revenue Growth Optimism Trend In The Global Pharmaceutical Industry By Region: North America, Europe, Asia-Pacific, Rest Of The World (% All Respondents), 2009-2010
Figure 4: Company Revenue Growth Optimism In The Global Pharmaceutical Industry Over The Next 12 Months: Cross-Industry Comparison (% All Respondents), 2010
Figure 5: Key Expected Changes In Business Structure In The Global Pharmaceutical Companies Industry (% Pharmaceutical Manufacturer Respondents), 2010
Figure 6: Key Expected Changes In Business Structure In The Global CRO / CMO Company Industry (% CRO / CMO Company Respondents), 2010
Figure 7: Key Expected Changes In Business Structure In The Global Pharmaceutical Industry Supplier Industry (% Pharmaceutical Industry Supplier Respondents), 2010
Figure 8: Merger And Acquisition Activity Expectations Over The Next 12 Months In The Global Pharmaceutical Manufacturer Industry (% Pharmaceutical Manufacturer Industry Respondents), 2009-2010 Trend Forecast
Figure 9: Merger And Acquisition Activity Expectations Over The Next 12 Months In The Global CRO / CMO Company Industry: (% CRO / CMO Company Industry Respondents), 2009-2010 Trend Forecast
Figure 10: Merger And Acquisition Activity Expectations Over The Next 12 Months In The Global Pharmaceutical Industry Supplier Industry (% Pharmaceutical Industry Supplier Industry Respondents), 2009-2010 Trend Forecast
Figure 11: Pharmaceutical Manufacturer Industry: Market Predictions Of The Fastest And Slowest Growing Regions (% Pharmaceutical Manufacturer Respondents), 2010
Figure 12: CRO / CMO Company Industry: Market Predictions Of The Fastest And Slowest Growing Regions (% CRO / CMO Company Respondents), 2010
Figure 13: Pharmaceutical Industry Supplier Industry: Market Predictions Of The Fastest And Slowest Growing Regions (% Pharmaceutical Industry Supplier Respondents), 2010
Figure 14: Pharmaceutical Manufacturer Predictions Of The Fastest And Slowest Growing Industry Sectors (% Pharmaceutical Manufacturer Respondents), 2010
Figure 15: CRO / CMO Company Predictions Of The Fastest And Slowest Growing Industry Sectors (% CRO / CMO Company Respondents), 2010
Figure 16: Pharmaceutical Industry Supplier Predictions Of The Fastest And Slowest Growing Industry Sectors (% Pharmaceutical Industry Supplier Respondents), 2010
Figure 17: Global Pharmaceutical Industry Predictions Of The Fastest And Slowest Growing Industry Sectors By Region: North America, Europe, Asia-Pacific, Rest Of The World (% 'Very Strong Growth' And 'Strong Growth' Combined, All Respondents), 2010
Figure 18: Leading Business Concerns For The Period 2010-2011 Among Global Pharmaceutical Industry Buyers And Suppliers (% All Respondents), 2010
Figure 19: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. Vs. Pharmaceutical Industry Supplier Vs.: Leading Business Concerns For The Period 2010-2011 Among Global Pharmaceutical Industry Buyers And Suppliers (% All Respondents), 2010
Figure 20: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Supplier Responses Vs. All Buyer Responses (% All Respondents), 2010
Figure 21: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. (% Buyer Respondents), 2010
Figure 22: The Most Important Actions For Suppliers To Take To Maintain And Secure Buyer Business In The Global Pharmaceutical Industry: Analysis Of All Buyer Respondents By Region (% Buyer Respondents), 2010
Figure 23: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. (% All Buyer Respondents), 2010
Figure 24: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. (% All Buyer Respondents), 2009
Figure 25: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry By Company Turnover (% All Buyer Respondents), 2010
Figure 26: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry By Company Turnover (% All Buyer Respondents), 2009
Figure 27: Annual Procurement Budgets In Us$ In The Global Pharmaceutical Industry By Region (% All Buyer Respondents), 2010
Figure 28: Projected Procurement Cost Savings Targets In The Global Pharmaceutical Industry For 2010-2011: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. (% All Buyer Respondents), 2010
Figure 29: Projected Procurement Cost Savings Targets In The Global Pharmaceutical Industry For 2010-2011 By Region: (% All Buyer Respondents), 2010
Figure 30: Projected Procurement Cost Savings Targets In The Global Pharmaceutical Industry For 2010-2011 By Leading Business Concern (Cost Containment): (% All Buyer Respondents), 2010
Figure 31: Average Identified Procurement Savings Target In The Global Pharmaceutical Industry Over The Next 12 Months: Global Pharmaceutical Industry Vs. Other Industries (% All Respondents), 2010
Figure 32: Expected Change In Total Procurement Spend In The Global Pharmaceutical Industry Over The Next 12 Months: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents) 2010 (With Comparison To 2009 Expectations)
Figure 33: Expected Change In Total Procurement Spend In The Global Pharmaceutical Industry Over The Next 12 Months By Region (% All Buyer Respondents), 2010 (With Comparison To 2009 Expectations)
Figure 34: Future Change In Spend In The Global Pharmaceutical Industry By Product And Service Category: Pharmaceutical Manufacturer - Expected Increase Or Decrease Over The Next 12 Months (% Pharmaceutical Manufacturer Respondents), 2010
Figure 35: Future Change In Spend In The Global Pharmaceutical Industry By Product And Service Category: CRO / CMO Company - Expected Increase Or Decrease Over The Next 12 Months (% CRO / CMO Company Respondents), 2010
Figure 36: Future Change In Spend In The Global Pharmaceutical Industry By Product And Service Category: Expected Increase Over The Next 12 Months Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010
Figure 37: Future Change In Spend In The Global Pharmaceutical Industry By Product And Service Category: Expected Increase Over The Next 12 Months Among All Buyers By Company Turnover (% All Buyer Respondents), 2010
Figure 38: Future Change In Spend In The Global Pharmaceutical Industry By Product And Service Category: Expected Increase Over The Next 12 Months Among All Buyers By Region (% All Buyer Respondents), 2010
Figure 39: Critical Success Factors For Selecting A Pharmaceutical Industry Supplier: Difference In Views, Buyers Vs. Suppliers (Net Difference In Ranking), Global, 2010
Figure 40: Critical Success Factors For Selecting A Pharmaceutical Industry Supplier: Buyer Vs. Supplier Comparison (% All Respondents), Global, 2010
Figure 41: Critical Success Factors For Selecting A Pharmaceutical Industry Supplier: Pharmaceutical Manufacturer Vs. CRO / CMO Company Comparison (% All Buyer Respondents), Global, 2010
Figure 42: Expected Future Changes In Procurement Objectives In The Global Pharmaceutical Industry (% All Buyer Respondents), 2010
Figure 43: Expected Future Changes In Procurement Objectives In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company Vs. (% All Buyer Respondents), 2010
Figure 44: Expected Future Changes In Procurement Objectives In The Global Pharmaceutical Industry By Company Turnover (% All Buyer Respondents), 2010
Figure 45: Expected Changes In Procurement Strategy In The Global Pharmaceutical Industry To Drive Value Across The Business (% All Buyer Respondents), 2010
Figure 46: Expected Changes In Procurement Strategy In The Global Pharmaceutical Industry To Drive Value Across The Business: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010
Figure 47: Expected Changes In Procurement Strategy In The Global Pharmaceutical Industry To Drive Value Across The Business: All Buyers By Region (% All Buyer Respondents), 2010
Figure 48: Critical Strategies Adopted By Buyers To Ensure Business Continuity In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010
Figure 49: Critical Strategies Adopted By Buyers To Ensure Business Continuity In The Global Pharmaceutical Industry By Region: (% All Buyer Respondents), 2010
Figure 50: Actions Undertaken By Buyers To Survive Product/Service Inflation And/Or Supply Shortages In The Global Pharmaceutical Industry: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010
Figure 51: Actions Undertaken By Buyers To Survive Product/Service Inflation And/Or Supply Shortages In The Global Pharmaceutical Industry By Region: Pharmaceutical Manufacturer Vs. CRO / CMO Company (% All Buyer Respondents), 2010 Skip to top